The combination of the anti-LAG-3 BMS-986016 (relatlimab) plus nivolumab strengthens the response in melanoma patients who are resistant to anti-PD-1/anti-PD-L1 therapy [158] (NCT01968109). The gene discussed is CD274; the disease is melanoma.